TSLA
Tesla
-- 230.580 NVDA
NVIDIA
-- 108.760 PLTR
Palantir
-- 78.050 AAPL
Apple
-- 220.840 GRRR
Gorilla Technology
-- 26.990 
NEWS
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Jaguar Health (NASDAQ:JAGX) will report results of its Phase 3 OnTarget trial for crofelemer, a cancer supportive care drug, on July 23, 2024. The company will hold an investor webcast at 8:30 AM Eastern to discuss the results and provide updates on its cancer supportive care portfolio. The webcast will feature Jaguar's scientific team, patient advocates, and oncology experts focusing on cancer therapy-related diarrhea (CTD) and oral mucositis.
Jaguar has expanded its 'Make Cancer Less Shitty' (MCLS) patient advocacy program, incorporating MCLS Ambassadors who are cancer survivors. The company also entered a 5-year U.S. in-license agreement for Gelclair, an FDA-approved oral mucositis product. These initiatives aim to address the significant impact of treatment side effects on cancer patients' quality of life and treatment adherence.
Jaguar has expanded its 'Make Cancer Less Shitty' (MCLS) patient advocacy program, incorporating MCLS Ambassadors who are cancer survivors. The company also entered a 5-year U.S. in-license agreement for Gelclair, an FDA-approved oral mucositis product. These initiatives aim to address the significant impact of treatment side effects on cancer patients' quality of life and treatment adherence.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment